Neuren Pharmaceuticals Limited

ASX:NEU ISIN:NZNEUE0001S8

Neuren Pharmaceuticals Limited (ASX:NEU) is developing new therapies for highly debilitating neuro-developmental disorders that emerge in early childhood and are characterised by impaired connections and signalling between brain cells. Neuren's deep expertise in neuro-developmental disorder therapy has been accumulated over years of clinical development.

 
  

News

Neuren Pharmaceuticals (ASX:NEU) To Get US$5.5M Additional Funding for US Army Clinical Trial of NNZ-2566

🕔9/5/2008 9:36:53 AM 4618

Neuren Pharmaceuticals (ASX:NEU)(PINK:NURPF) announced that the Company has been informed that an additional US$5.5 million in funding will be made available by the US Army for the Company's planned Phase II clinical trial of NNZ-2566 in traumatic brain injury (TBI). With the previously announced grant of US$4 million to cover direct costs of the study, this results in a total commitment of approximately US$10 million.

Read Full Article

Conference Call Half Year 2008 Results

🕔7/22/2008 10:03:00 PM 2275

adidas AG Dear journalist,

Read Full Article

MPH Ventures Continues To Significantly Expand

🕔7/22/2008 6:03:00 PM 2292

MPH Ventures Corp. (OTC: MPSFF) Suite 2230 - 885 West Georgia Street, Vancouver, BC, Canada, V6C 3E8 www.mphventurescorp.com

Read Full Article

Granville Baird Acquires Meier Vakuumtechnik And Makes Major Investment In The Alternative Energy Market

🕔7/21/2008 7:33:00 PM 3495

Granville Baird GmbH Bocholt/ Hamburg, 21.07.2008. Private equity investor Granville Baird acquires a majority stake in Meier Vakuumtechnik GmbH as part of a management buy-out. Meier specializes in the development, production and sales of equipment for manufacturing photovoltaic panels. Considerable worldwide growth is expected in this market as electricity generation from solar sources will continue to expand.

Read Full Article

Neuren Pharmaceuticals (ASX: NEU) Announce Glypromate(R) and NNZ-2566 Included in 10 Most Promising Neuroscience Projects by Windhover

🕔7/21/2008 2:06:36 PM 4591

Neuren Pharmaceuticals (ASX:NEU)(PINK:NURPF) announced today that Glypromate(R) and NNZ-2566 for neuroprotection in cardiopulmonary bypass and traumatic brain injury (TBI) have been selected as one of the Top 10 most promising neuroscience projects available for partnering by an independent committee assembled by Windhover Information, a leading provider of business information products and services to senior executives in the pharmaceutical, biotechnology, and medical device industries.

Read Full Article

Neuren Pharmaceuticals Limited ASX: NEU - Further Validation of NNZ-2566 as a Traumatic Brain Injury Treatment - Mr David Clarke, CEO

🕔2/14/2007 11:43:00 AM 2997

Neuren Pharmaceuticals Limited (ASX: NEU) - Further Validation of NNZ-2566 as a Traumatic Brain Injury Treatment - Mr David Clarke, CEO; Boardroomradio is pleased to announce that Neuren Pharmaceuticals Limited (ASX: NEU) has published an audio file.

Read Full Article
###

4,341 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 3) (Last 30 Days: 27) (Since Published: 4341) 

Company Data

    Headquarters
  • Suite 201, 697 Burke Road
    Camberwell, Victoria 3124
    Australia
  • Telephone
  • +61 (3) 9092 0480 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Healthcare 
  • Homepage
  • www.neurenpharma.com

More News Results

  • 2025/05/09: Update - Notification of buy-back - NEU*
  • 2025/05/08: Update - Notification of buy-back - NEU*
  • 2025/05/08: DAYBUE Q1 2025 net sales US$84.6m up 11% from Q1 2024*
  • 2025/05/07: Update - Notification of buy-back - NEU*
  • 2025/05/06: Notification of cessation of securities - NEU*
  • 2025/05/06: Update - Notification of buy-back - NEU*
  • 2025/05/05: Becoming a substantial holder*
  • 2025/05/05: Update - Notification of buy-back - NEU*
  • 2025/05/02: Neuren appoints Daryl DeKarske to executive team*
  • 2025/05/02: Update - Notification of buy-back - NEU*
*refer to company website

Social Media